Medical devices, healthcare technology and the business of care
PMA approval · P040014

IBI THERAPY CARDIAC ABLATION SYSTEM ERS/ 1500T RF GENERATOR

Irvine Biomedical, Inc. · Decision date Jan 14, 2005

MEDTECHLEDGER EXPLANATIONP040014

What did the FDA approve?

The FDA database entry for P040014 records an original PMA approval dated January 14, 2005, for the IBI Therapy Cardiac Ablation System from Irvine Biomedical, Inc. The approval statement describes the device as indicated for mapping and for use with a compatible RF generator for three specific purposes: interruption of accessory atrioventricular conduction pathways associated with tachycardia, treatment of AV nodal re-entrant tachycardia, and creation of complete AV nodal block in patients with a difficult to control ventricular response to an atrial arrhythmia.

The entry lists no supplement type or supplement reason, so no changed item or post-approval modification is described. The product code is LPB and the specialty is cardiovascular. The statement reports the device's stated purpose; it does not by itself provide independent evidence of safety or clinical effectiveness. No information is provided about clinical data, trial results, or comparative performance.

FDA approval order statement

APPROVAL FOR THE IBI THERAPY CARDIAC ABLATION SYSTEM. THE DEVICE IS INDICATED FOR MAPPING AND FOR USE WITH A COMPATIBLE RF GENERATOR FOR: INTERRUPTION OF ACCESSORY ATRIOVENTRICULAR (AV) CONDUCTION PATHWAYS ASSOCIATED WITH TACHYCARDIA; THE TREATMENT OF AV NODAL RE-ENTRANT TACHYCARDIA (AVNRT); OR CREATION OF COMPLETE AV NODAL BLOCK IN PATIENTS WITH A DIFFICULT TO CONTROL VENTRICULAR RESPONSE TO AN ATRIAL ARRHYTHMIA.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Jan 14, 2005

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P040014
Regulatory pathway
Premarket approval application
Product code
LPB
Decision code
APPR
Decision date
Jan 14, 2005
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Cardiac ablation percutaneous catheter.

Product code
LPB
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P040014 received

    Application receipt date recorded by FDA.

  2. P040014 · FDA decision

    APPR

  3. P040014/S052 · Related supplement

    Therapy (including Bi-Directional and 4mm Thermistor) Ablation Catheter

Timeline entries are records held by MedtechLedger for P040014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P040014

Product / regulatory recordCompanyPathwayDecision dateSource
Irvine Biomedical, Inc.PMA supplementSep 3, 2026FDA

Explore the linked device profile

Other records with product code LPB

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Irvine Biomedical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2375 Morse Ave., Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records